Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 323 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Topical study cream Clear all
Terminated Phase 2 Interventional Results available

Topical Sodium Nitrite in Sickle Cell Disease and Leg Ulcers

NCT02863068
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Topical Sodium Nitrite, Placebo
Drug · Other
Lead sponsor
caterina P minniti
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
The Bronx, New York • Durham, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 3 Interventional Results available

Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies.

NCT02978508
View directory record Official record
Conditions
Scabies
Interventions
Permethrin Cream, 5%, Elimite
Drug
Lead sponsor
Mayne Pharma International Pty Ltd
Industry
Eligibility
12 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Miami, Florida • Richland, Washington
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women

NCT02364882
View directory record Official record
Conditions
Female Sexual Health
Interventions
Sildenafil
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 3 Interventional Results available

Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers

NCT01594762
View directory record Official record
Conditions
Diabetic Foot Infection
Interventions
Topical pexiganan cream 0.8%, Topical placebo cream, Standard wound care
Drug · Other
Lead sponsor
Dipexium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 19, 2026, 10:46 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Use of Topical Testosterone and Estrogen vs Estrogen Alone in Vulvodynia: a Randomized Controlled Trial

NCT07260825
View directory record Official record
Conditions
Vulvodynia, Dyspareunia, Lichen Sclerosus of Vulva
Interventions
Estradiol 0.01% Vag Cream, testosterone 0.1% and estradiol 0.01% vaginal cream
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris

NCT01631474
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CB-03-01, Vehicle
Drug
Lead sponsor
Intrepid Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Sanford, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 3 Interventional

S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Non-Ablative Facial Laser Resurfacing in Adults

NCT00110747
View directory record Official record
Conditions
Pain
Interventions
S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%), Placebo Peel
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
3
States / cities
Clinton Township, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 4 Interventional Results available

Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses

NCT00774787
View directory record Official record
Conditions
Actinic Keratoses
Interventions
imiquimod 5% cream
Drug
Lead sponsor
Rigel Dermatology
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
St. Petersburg, Florida • Henderson, Nevada • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 3 Interventional

Low-Dose Testosterone in Improving Libido in Postmenopausal Female Cancer Survivors

NCT00075855
View directory record Official record
Conditions
Cancer Survivor, Sexual Dysfunction, Sexuality and Reproductive Issues, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
therapeutic testosterone, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
16
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Urbana, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Tetrix Cream in the Healing of Injured Skin in Subjects With Contact Dermatitis

NCT00643214
View directory record Official record
Conditions
Healthy
Interventions
Tetrix
Device
Lead sponsor
Coria Laboratories, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 22, 2008 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Botulinum Toxin Type A Injection After Topical Anesthesia Versus Petrolatum Ointment

NCT03799484
View directory record Official record
Conditions
Forehead Rhytides, Forehead Wrinkles
Interventions
Botulinum toxin type A, 2.5% lidocaine/2.5% prilocaine, petrolatum ointment
Drug · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 4 Interventional

Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis

NCT01202149
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)
Device
Lead sponsor
Frankel, Amylynne, M.D.
Other
Eligibility
2 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 3 Interventional

Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults

NCT05203315
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Duobrii 0.01 % / 0.045 % Topical Lotion, CeraVe, Topical Cream
Drug
Lead sponsor
Austin Institute for Clinical Research
Network
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Houston, Texas • Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 19, 2026, 10:46 PM EDT
Terminated Phase 2 Interventional Results available

Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis

NCT04846348
View directory record Official record
Conditions
Cutaneous Mastocytoses
Interventions
Topical preparation of sodium cromolyn 5%, diphenhydramine 1% and trolamine salicylate 10% in emollient cream base.
Combination Product
Lead sponsor
Joseph Butterfield
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 2 Interventional

A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis

NCT06923228
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
CGB-500 Ointment with 1% tofacitinib, Ruxolitinib 1.5% Cream QD
Drug
Lead sponsor
CAGE Bio Inc.
Industry
Eligibility
12 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma

NCT02977507
View directory record Official record
Conditions
Melasma
Interventions
Lytera 2.0, 4% Hydroquinone Topical Cream, SkinMedica Facial Cleanser, SkinMedica Rejuvenative Moisturizer, SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen
Other · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 19, 2026, 10:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Lipid Profile of the Skin Surface in Acne

NCT02180425
View directory record Official record
Conditions
Acne
Interventions
Tretinoin or Adapalene, Isotretinoin
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
12 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
2
States / cities
Davis, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 19, 2026, 10:46 PM EDT
Terminated Phase 4 Interventional Results available

Hormonal Status on Blood Flow and Tissue in Pelvic Organ Prolapse

NCT01886794
View directory record Official record
Conditions
Pelvic Floor Disorders
Interventions
Postmenopausal, topical vaginal estrogen cream, Placebo Comparator: Postmenopausal, topical placebo cream
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
21 Years to 70 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Not applicable Interventional Results available

Study of Topical Superoxide Dismutase to Treat Radiation Induced Fibrosis

NCT01771991
View directory record Official record
Conditions
Radiation Induced Fibrosis to the Head and Neck
Interventions
Topical Sodermix Dismutase in the form of Sodermix (SOD), Placebo
Drug
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of SST 0225, a Topical Ibuprofen Cream, in the Treatment of Pain Associated With Acute Ankle Sprain

NCT01874626
View directory record Official record
Conditions
Acute Ankle Sprain
Interventions
Placebo, SST-0225 Topical Ibuprofen Cream
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
16 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Guilford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 4 Interventional Results available

A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis

NCT05680740
View directory record Official record
Conditions
Psoriasis
Interventions
VTAMA® (tapinarof) Cream 1%
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Fort Smith, Arkansas • Los Angeles, California • Boca Raton, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Vibrating, Cold Device for Pediatric Intravenous (IV) Cannulation Pain Relief

NCT01394250
View directory record Official record
Conditions
Pain, Anxiety
Interventions
Buzzy, Topical Lidocaine 4% Cream
Device · Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Years to 18 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2016 · Synced Oct 19, 2026, 10:46 PM EDT
Not listed Phase 2 Interventional

Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)

NCT00652184
View directory record Official record
Conditions
Herpes Zoster, Postherpetic Neuralgia
Interventions
ARYS-01 (sorivudine) cream 3% or placebo cream, placebo, valaciclovir
Drug
Lead sponsor
aRigen Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Beverly Hills, California • Encino, California • Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2008 · Synced Oct 19, 2026, 10:46 PM EDT
Completed Phase 1 Interventional

Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa

NCT02793960
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
topical BPM31510 3.0% Cream
Drug
Lead sponsor
Shasa Hu
Other
Eligibility
12 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 19, 2026, 10:46 PM EDT